Dr. Ruba presents a case study highlighting treatment approach with acalabrutinib and focus on safety profile of BTKi.
Dr. Ruba Taha, Qatar
Dr. Ruba Taha, Consultant Clinical Haematologist, Hamad Medical Corporation, Qatar, elaborates 2nd GCC Haematology forum- CLL case discussion Focus on safety profile of BTKi.
• Discusses a patient case with his background and treatment approach with acalabrutinib, summarises 3 clinical trial data.
• Serious adverse events from FLAIR trial, GLOW trial
• Updated Ibrutinib smpc for serious cardiac events. In the later section
• Clinical evidence of acalabrutinib over Ibrutinib from ELEVATE-TN trial data
• ALPINE study: Zanubrutinib in head-to-head comparison with Ibrutinib.
• NCCN guidelines treatment regime for CLL/SLL.
Explore more videos
CLL Case Presentation
Dr. Khalil Al Farsi, Oman
Expert Guidance for the Treatment of CLL
Dr. Susan M. O'Brien, US
Panel discussion
Dr. Ayman Al Hejazi, KSA